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Abstract
Purpose To examine the relations between patient-reported outcomes (PROs) within a conceptual model for adults with
sickle cell disease (SCD) ages 18 – 45 years enrolled in the multi-site Sickle Cell Disease Implementation Consortium
(SCDIC) registry. We hypothesized that patient and SCD-related factors, particularly pain, and barriers to care would independently contribute to functioning as measured using PRO domains.
Methods Participants (N = 2054) completed a 48-item survey including socio-demographics and PRO measures, e.g., social
functioning, pain impact, emotional distress, and cognitive functioning. Participants reported on lifetime SCD complications,
pain episode frequency and severity, and barriers to healthcare.
Results Higher pain frequency was associated with higher odds of worse outcomes in all PRO domains, controlling for
age, gender and site (OR range 1.02–1.10, 95% CI range [1.004–1.12]). Reported history of treatment for depression was
associated with 5 of 7 PRO measures (OR range 1.58–3.28 95% CI range [1.18–4.32]). Fewer individual barriers to care
and fewer SCD complications were associated with better outcomes in the emotion domain (OR range 0.46–0.64, 95% CI
range [0.34–0.86]).
Conclusions Study results highlight the importance of the biopsychosocial model to enhance understanding of the needs of
this complex population, and to design multi-dimensional approaches for providing more effective interventions to improve
outcomes.
Keywords Patient-reported outcome measures · Sickle cell disease · Implementation science · Models—biopsychosocial

Plain English summary
Sickle cell disease (SCD) is a rare, inherited blood disorder that causes serious and life-threatening complications including pain, stroke and anemia. It is important to
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understand the burden of the disease, particularly as patients
get older, but there are few studies in this area. Patientreported outcomes (PROs) communicate information about
aspects of patients’ lives that can only be provided from
their point of view. Our goal was to examine how PROs
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were inter-related with pain and other sickle cell complications, barriers to care and other social variables for adults
with SCD. We gained valuable insights into the impact of
pain, depression, employment and income on quality of life
for adults with SCD, as measured by the PROs in our study,
and we showed how important barriers to care can be. We
contributed to the knowledge base about PRO measurement
in SCD. PRO measures thus provide meaningful information for providers and patients to improve quality of life, and
the most effective interventions to improve health outcomes
must be multi-dimensional.

Introduction
The routine assessment of patient-reported outcomes (PROs)
in clinical settings lends to creating a patient-centered environment, by enhancing communication and shared-decision
making, improving satisfaction, and allowing for monitoring
improvement or deterioration of health status [1]. In clinical trials, PROs complement measures of efficacy such as
survival and healthcare utilization, allowing translation of
results into some benefits that can only be evaluated with
patients’ reports.
Sickle cell disease (SCD) is a rare, inherited blood disorder in the U.S., affecting about 100,000 individuals, primarily African Americans [2]. The clinical manifestations
of the disease include recurrent, unpredictable and severe
acute pain episodes; chronic pain; cerebrovascular disease,
including overt stroke; and other serious complications such
as renal and cardiopulmonary disease. These manifestations
can lead to significant impairment as assessed using PROs
[3, 4], and an increased burden of disease as patients age [5].
The National Heart, Lung and Blood Institute (NHLBI),
in collaboration with a range of sickle cell stakeholders,
developed the Adult Sickle Cell Quality of Life Measurement Information System (ASCQ-Me®) to provide a means
of systematically evaluating disease-specific PRO domains
impacted for the growing population of adults with SCD
[6]. The ASCQ-Me development used advanced knowledge
of psychometrics as it aligned with the development of the
National Institutes of Health’s Patient-Reported Outcomes
Measurement Information System (PROMIS®).
Previous research has shown that adults and children with
SCD who received the disease modifying therapy hydroxyurea, compared to those who did not, reported better PROs
[7–10]. Demographic factors associated with worse PRO
scores for adults with SCD include age and sex [11, 12].
Other factors associated with worse PRO scores include
SCD complications, particularly pain [13, 14].
As lifespans have increased, disparities in quality of life
and quality of care are also evident for adults with SCD,
including lower socioeconomic status [15, 16], stigma,
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discriminatory treatment in healthcare settings [17], lack
of social support, isolation, and cognitive challenges [6,
18–20]. The prevalence of depression and anxiety is two to
three times the national average [21].
A few studies have delineated how this range of challenges, manifested by scores on PROs measures, are associated with healthcare utilization. For example, lower
education was found to be independently associated with
potentially avoidable emergency department (ED) care [22].
Young adults with worse PRO scores evidenced more frequent SCD-related hospitalizations and ED visits and/or
longer hospitalizations [7, 22, 23]. The three-year Comprehensive Sickle Cell Centers (CSCC) Collaborative Data Project that began in 2005 included 1046 participants (median
age 28.0 years, 48% male, 73% SS or Sβ0 thalassemia) [5].
Participants reported impaired health related quality of life
(HRQoL) on all but the mental health domain on the SF-36,
particularly with increasing age [5]. Pain episodes, asthma,
or avascular necrosis were associated with worse SF-36 scale
scores as was chronic opioid use. Female gender was associated with impaired physical function and vitality scale scores
and chronic antidepressant use was associated with worse
scores on bodily pain, vitality, social functioning, emotional
role, and mental health scales. Few studies have examined
the inter-relations between PROs and different patient- and/
or SCD-related variables within a conceptual model. Conceptual models may allow us to advance our understanding
of how the disease and treatments affect individuals, as more
treatment options become available.
The Sickle Cell Disease Implementation Consortium
(SCDIC) was established by NHLBI in 2016 to identify and
address barriers to quality care in SCD [24]. A key activity
was to engage eight sites in diverse regions in the U.S. to create a registry of a minimum of 2400 adolescents and adults
with SCD. The goal of the SCDIC registry is to enhance
our understanding of SCD acute and chronic complications/
comorbidities and treatments, as well as HRQoL and PROs
for a modern cohort. We recently described the SCDIC registry methodology [25] and the preliminary evaluation of
PROs in this population [26].
The purpose of the present analysis is to examine
the relations between PROs within a conceptual model
for adults with SCD ages 18–45 years enrolled in the
SCDIC registry. The PRO domains assessed—emotional,
pain, fatigue and sleep impacts, and social and cognitive functioning—are influenced by SCD complications,
disease modifying therapies, socio-demographics, barriers to care and healthcare utilization. The conceptual
model was developed from prior formative research [6],
and from the SCDIC's Conceptual Framework for PROs/
HRQoL in SCD [27], with input from other national and
international experts in the area of PROs in SCD. Figure 1 shows the inter-relations between different variables
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Fig. 1  Conceptual model for inter-relations of patient-reported outcomes (PROs) in sickle cell disease (SCD). The model includes
the inter-relations of four PRO groups (emotional distress, social
functioning, pain impact, and fatigue, sleep and cognitive functioning) with health behaviors (acute healthcare utilization and preventive care), SCD complications (number of complications and pain

frequency/severity), SCD-related factors (genotype, hydroxyurea,
chronic transfusion history), patient related factors (education,
employment, income, marital status, diabetes and depression) and
barriers to care (systemic and individual). All inter-relations are
adjusted for age and gender identity

along with their impact on PROs. Our conceptual model
reflects prior research on the inter-relations among variables such as barriers to care [28], utilization patterns [29],
morbidity [30], and socio-demographic factors [31, 32]
and health outcomes. We hypothesized that patient and

SCD-related factors as well as barriers to care would independently contribute to functioning as measured using the
PRO domains. We expected that the experience of pain
and other SCD-related complications would account for
a significant degree of the relation between the variables.
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Method
Participants and procedures
Adolescents and adults with SCD ages 15–45 years were
enrolled in the SCDIC registry during an 18-month period
between 2017 and 2018. Inclusion criteria was confirmed
SCD diagnosis (SS, SC, Sβ-thalassemia, other variants),
literate in English, and willing and cognitively able to provide informed consent and complete the Patient Enrollment Survey. SCD diagnosis was confirmed through medical record or confirmatory laboratory test. Individuals with
sickle cell trait (e.g., Hb AS), successful bone marrow
transplant for SCD, or unwilling/unable to provide consent were excluded. Our sub-sample included 2,054 adults
18—45 years and with completed Patient Enrollment Surveys and Medical Record Abstraction forms.
The study utilized convenience sampling from the eight
SCDIC sites, with some outreach into the community. Eligible participants were identified and recruited in-person
(e.g., clinic, outreach events), by phone, or via electronic
media (e.g., websites, chat rooms). Participants recruited
remotely provided verbal informed consent and submitted
signatures online. SCDIC research staff were available to
answer questions as needed while participants completed
the surveys. A member of the local study team completed
a medical record abstraction for each participant. Institutional review boards of all SCDIC sites provided approval,
with seven of the eight sites providing compensation for
participation. All data were collected at one point in time.
Details of study methodology were recently published
[26].

Measures
Participants completed a 48-item survey including sociodemographics and PRO measures. We did not use complete short forms for some ASCQ-Me® and PROMIS®
measures to reduce participant burden. However, the PROs
that were selected were developed using item response
theory (IRT), that allows for a range of administration and
tailoring options [33]. An IRT-calibrated item bank consists of items that correspond with level of symptom severity or function. Any number and combination of items
from the same bank can be scored and compared to all
other measures derived from the same item bank without
loss of precision in measurement of the construct [34].
Individual items were selected for their relevance from
domains by the SCDIC investigators. Of note, interpretation of scale scores must take into consideration that
the reference populations for ASCQ-Me® and PROMIS®
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differ, with the former consisting of adults with SCD and
the latter adults from the general population. Thus, the
“average” score of 50 for the PROMIS measures centers
on a sample of individuals that, collectively, matched the
U.S. 2000 Census on such demographics as gender, age,
race/ethnicity and education, while the “average” score
of 50 for the ASCQ-Me measures centers on a sample of
adults with SCD 18 years of age and older.
ASCQ-Me® Emotional Impact over the past seven
days was assessed using: How often did you … “feel completely hopeless because of your health?” and “were you
very worried about needing to go to the hospital?” ASCQMe® Social Functioning over the past 30 days was assessed
with: How much … “did you rely on others to take care of
you because of your health?” and “did your health make
it hard for you do things with your friends?” ASCQ-Me®
Pain Impact over the past seven days was assessed using:
How often … “did you have very severe pain?” and “did
you have pain so bad that it was hard to finish what you were
doing?” ASCQ-Me® Sleep Impact over the past seven days
was assessed using: How often did you … “stay up most
of the night because you could not fall asleep?” and “have
a lot of trouble falling asleep?” All ASCQ-Me items were
scored on a 5-point Likert scale (i.e., Never to Always). Item
responses were uploaded to HealthMeasures Scoring Service
at assessmentcenter.net, where T-scores and related statistics
were generated, using adults with SCD who participated in
the ASCQ-Me field test (n = 555) as the reference population [14]. The standardized T-score mean is 50 (standard
deviation (SD) = 10), with higher scores indicating better
outcomes.
The ASCQ-Me® Pain Episode question set includes five
questions regarding the frequency (number of severe pain
events in the last 12 months), timing (of most recent event)
and severity of the most recent pain event (duration and pain
interference). A Pain Episode composite was calculated by
creating standard scores for the pain episode frequency and
severity composites. A higher score indicates worse frequency, timing and severity of SCD pain.
Cognitive functioning over the past seven days was
assessed using the 8-item Neuro-QOL Cognitive Function
short form [35] with item responses on a 5-point Likert scale
(i.e., Never to Very Often). Item responses were uploaded
to the HealthMeasures Scoring Service, where T-scores and
related statistics were generated using PROsetta Stone Wave
2 as the reference population, which is representative of the
general adult population [36]. A higher T-score indicates
better cognitive function.
The 4-item, PROMIS® short form for Emotional Distress-Depression was used to assess depressive symptoms over the past seven days and items were scored on
a 5-point Likert scale (i.e., Never to Always). Crosswalk
tables have been established using rigorous methodology,
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to link such “legacy” depression measures as the Patient
Health Questionnaire (PHQ)-9, the Beck Depression Inventory-II (BDI-II) and the Center for Epidemiologic Studies
Depression Scale (CES-D) with the PROMIS® Emotional
Distress-Depression measure [37]. Analyses have shown that
PROMIS cutoff scores for depression severity correspond
with commonly used legacy measures [38].
A single item (“I felt tired”) from the PROMIS Fatigue
item bank was used to measure tiredness in the past seven
days, on a 5-point Likert scale from Not at All to Very Much.
Item responses were uploaded to the HealthMeasures Scoring Service, where T-scores and related statistics were generated using PROMIS Wave 1 as the reference population,
which is representative of the general adult population [39].
Higher T-scores on these PROMIS measures indicate worse
outcomes.
Participants reported on lifetime SCD complications
using the ASCQ-Me Medical History Checklist (MHC) [14],
modified and expanded by the SCDIC investigators from the
original list of nine to include 13 treatments and conditions
associated with SCD, answered “yes” or “no.” Treatments
included daily pain medicine and conditions included lung
problems (e.g., acute chest syndrome); kidney, eye, hip or
shoulder damage; asthma; pulmonary hypertension; heart
failure; blood clots; stroke; leg ulcers; and spleen damage or
removal. The score for the checklist is the number of questions with a “yes” response, thus a higher score indicates
a greater number of treatments or conditions. Participants
reported separately on two comorbidities—diabetes (“yes”
or “no”) and current or ever treated for depression. They
indicated their current use of disease modifying therapies
hydroxyurea and/or regular blood transfusions (“yes” or
“no”).
The SCD Barriers to Medical Care consists of 11 reasons
for experiencing delays or not receiving needed medical care
(“yes” or “no,” grouped into seven Access Barriers (e.g.,
distance from provider, insurance, challenges obtaining an
appointment) and four Individual Barriers (e.g., too busy,
previous bad experiences with the healthcare system) [12].
Finally, we tracked healthcare utilization (an aspect of
"Health Behaviors" shown in Fig. 1) utilizing (1) outpatient
visit with sickle cell specialist or primary care provider
within one year of enrollment (“yes” or “no”) and (2) number of acute care visits for pain in the past year, categorized
as 0, 1–2 or >  = 3 ED visits or hospital admissions, both
from medical record abstraction.

Statistical analyses
All analyses were performed on cross-sectional data, with
seven PROs (i.e., pain, sleep, emotional and social functioning impacts, emotional distress, tiredness, and cognitive
function) included in the analyses. Binary variables were
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created for all outputs using as cut-points one standard
deviation (SD) above the mean for PROs where a higher
T-score indicates a worse outcome (PROMIS® Emotional
Distress and Fatigue) [41] and one SD below the mean for
those where a higher T-score indicates a better outcome as
compared to the reference populations (ASCQ-Me® and
Neuro-QoL Cognitive Function) [32].
Baseline characteristics and distributions of risk factors
are presented as frequencies and percentages for categorical variables, and median and interquartile ranges (IQR) or
mean and SD for continuous variables. Categorical variables
were analyzed using chi-square, or Fisher’s exact test for
sparse tables. Continuous variables were compared using
t-test or Mann–Whitney U test, as appropriate.
Univariate analysis was used to evaluate potentially
significant variables for inclusion in multivariable models
for each PRO to identify factors independently associated
with better or worse outcomes. Variables with p <  = 0.10 in
univariate analysis were included in a multivariable logistic regression with backward elimination. Adherence with
hydroxyurea and healthcare utilization (ED and inpatient
visits) were not included in the models because not all participants were eligible for or prescribed hydroxyurea and
about 27% of records were missing data on utilization. Age,
gender and site were included and retained in all models
during stepwise reduction regardless of their statistical significance to control for potential confounding effects. To
account for multiple testing, a p-value = 0.01 was used as
the threshold for statistical significance in the multivariable
models. Odds ratios (OR) and corresponding 95% confidence intervals were obtained for variables remaining in the
final model. All analyses were conducted in SAS Version 9.4
(SAS Institute Inc., Cary, NC, USA).

Results
Socio‑demographics
The median age of the 2054 adults with SCD in this analysis was 28 years (Table 1), and the predominant age group
was 24–34 years (43.8%). Over half (56.8%) identified as
female, and the majority identified as African American/
Black (95.7%), with 4.5% reporting Hispanic ethnicity. The
most common educational attainment was some college
(35.2%), followed by high school graduate or equivalent
(30.3%), with 24.1% attaining a college or advanced degree.
Over a third (37.2%) were employed, 25.2% reported being
disabled and the remainder were not working, either due to
student status (13.5.%), or “other” (24.1%, e.g., maintaining their home or laid off). A significant proportion (74.2%)
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Table 1  Participant socio-demographics
Characteristic
Age
Mean (SD) years
Median (IQR)
18 to 24 years
25 to 34 years
35 to 45 years
Gender
Male
Female
Race/Ethnicity
Black/African American
Multi-racial
Other Race (American Indian/Alaska Native, Asian,
White)
Hispanic ethnicity
Highest Education
Some high school or less
High School (Graduate, GED or equivalent)
Some college
College graduate or advanced degree
Employment
Working now
Disabled
Student
Other (unemployed, retired)
Marital status
Married or living together
Never married
Not married (divorced/separated, widowed)
Insurance
Medicaid, other government-sponsored
Private
Medicare
None
Other
Annual household income
$25,000 or less
$25,000—$50,000
$50,001 or more
Household density
Mean (SD)
a

Table 2  Clinical characteristics, barriers to care and health behaviors
N = 2054
29.1 (7.2)
28 (23–35)
n (%)
641 (31.2)
900 (43.8)
513 (25.0)
888 (43.2)
1166 (56.8)
1918 (95.7)
67 (3.3)
20 (0.9)
91 (4.5)
209 (10.4)
612 (30.3)
711 (35.2)
487 (24.1)
748 (37.2)
507 (25.2)
272 (13.5)
485 (24.1)
313 (16.2)
1499 (77.6)
120 (6.2)
1216 (59.2)a
567 (27.6)
468 (22.8)
83 (4.0)
16 (0.8)
998 (54.6)
403 (22.1)
426 (23.3)

Percentages add up to greater than 100% as more than one option
could be selected
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Characteristic
From patient survey
ASCQ-Me Medical History Checklist
Median (IQR)
Range
Sickle cell disease diagnosis
Hb SS or Sβ0 thalassemia
Hb SC
Hb Sβ + thalassemia and other variants
Diabetes
Yes
No
Ever treated for depression
Yes, current
Yes, previous
No
Hydroxyurea use and adherence
Yes, adherent (6–7 of 7 days)
Yes, partially adherent (2–5 of 7 days)
Yes, not adherent (0–1 of 7 days)
No, not currently using
Regular blood transfusions for SCD
Yes
No
Barriers to Care
Access/Accommodations/Insurance
No barriers
1–2 barriers
3 or more barriers
Individual barriers
No barriers
1–2 barriers
3 or more barriers
From Medical Record Abstractions:
Outpatient visit to hematologist or primary care provider within past 12 months
Yes
No
Unknown
Emergency department (ED) and inpatient admissions
for pain within past 12 months
No ED or inpatient admissions
1–2 ED or inpatient admissions
3 or more ED or inpatient admissions
a

N = 2054

3 (2)
0–12
n (%)
1490 (72.6)
432 (21.1)
130 (6.3)
53 (2.6)
1953 (97.4)
181 (9.2)
330 (16.8)
1455 (74.0)
628 (31.3)
250 (12.5)
91 (4.5)
1035 (51.7)
587 (28.8)
1449 (71.2)

1681 (81.8)
302 (14.7)
71 (3.3)
1683 (81.9)
323 (15.7)
48 (2.3)

1893 (92.2)
92 (4.5)
69 (3.4)

279 (18.7)
388 (26.0)
823 (55.2)

Patients with missing data are not included in calculations of percentages unless otherwise specified
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were never married and over half (54.6%) reported an annual
income under $25,000, while the mean household density
was 3. Like other SCD populations, almost 60% had Medicaid or other government-sponsored insurance.

Clinical characteristics, health behaviors
and barriers to care
The majority (72.6%) of participants were diagnosed with
sickle cell anemia (SCD genotypes SS or Beta 0 thalassemia—Table 2). Of thirteen potential SCD treatments/complications, participants reported a median of 3 treatments/
complications on the ASCQ-Me MHC with 38.7% reporting three or more treatments/complications, 38.7% reporting 2—3 and 22.6% reporting 0—1 SCD-related treatments/
complications. Less than three percent reported a diagnosis
of diabetes, and 26% reported current or previous treatment
for depression. Forty-eight percent were currently using
hydroxyurea and 28.8% were currently receiving regular
blood transfusions. Over 80% of participants reported no
barriers to needed healthcare, with 18.2% reporting 1 or
more Access barriers and 18.1% reporting 1 or more Individual barriers. Almost all (92.2%) participants had outpatient visits with their primary care provider or SCD specialist within the past year. More than half (55.2%) had three or
more ED or inpatient admissions for acute pain episodes in
the past year (27% missing data). For ASCQ-Me® Pain Episode Frequency and Severity T-scores, means and standard
deviations were similar to the reference sample, with a pain
episode frequency mean (SD) of 49.2 (11) and pain severity
mean (SD) of 50.8 (9.7).

Patient‑reported outcomes: multivariable models
On the ASCQ-Me® measures, means and standard deviations were similar to the reference sample. Using the Emotional and Social Functioning Impact measures, participants
reported mean (SD) scores of 50.5 (8.8) and 51.2 (9.7)
respectively and only a few reported T-scores less than 40,
with 12.7% reporting worse emotional impact and 14.8%
reporting worse social functioning compared to the population norms. Somewhat higher percentages of participants
reported T-scores less than 40 for Pain (mean (SD) of 47.1
(9.0)) and Sleep Impact (mean (SD) of 49.2 (9.7)), with
21.5% reporting worse impact of pain and 16.9% reporting
worse sleep impact. For Neuro-Qol Cognitive Functioning,
the mean (SD) was 50.3 (9.1) with 12.9% of the sample
reporting impaired cognitive functioning (T-score < 40).
For PROMIS Emotional distress, the mean (SD) was
50.9 (9.6), with 20.1% reporting worse emotional distress
(T-score > 60). Finally, for PROMIS® Fatigue (tiredness),
the mean (SD) was 55.4 (9.5) with 22% reporting worse
tiredness (T-score > 60).
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Results for univariate models can be found in supplemental materials (Table S1). Based on these results, age, gender,
income, employment status, marital status, ever treated for
depression, access and individual barriers to care, pain frequency and severity, and number of reported complications
were entered in the multivariable models according to our
selection criteria for each outcome.
In the multivariable model for Emotional Impact
(Table 3) ever treated for depression, and pain frequency
and severity were associated with higher odds for worse
outcomes, while fewer individual barriers to care and fewer
than three complications on the MHC were associated with
better outcomes on Emotional Impact. Employment (disabled or “other” status), ever treated for depression, and pain
frequency and severity were associated with higher odds
for worse social functioning in the multivariable model for
Social Functioning Impact, while fewer individual barriers to care were associated with lower odds of worse social
functioning impact. In the model for Pain Impact, disabled
and “other” employment status and higher pain frequency/
severity was associated with higher odds of poor outcomes.
In the model for Sleep Impact, ever treated for depression,
income less than $50,000, and increased pain frequency and
severity were associated with worse outcomes while fewer
than three complications on the MHC were associated with
lower odds for poor outcomes. For Neuro-QoL® Cognitive
Function, ever treated for depression and income of $25,000
and less were associated with higher odds for worse cognitive functioning, while fewer access barriers to care were
associated with lower odds for poor cognitive functioning.
In the multivariable model for PROMIS Emotional Distress, incomes of $25,000 and less, ever treated for depression and higher pain frequency were associated with higher
odds for worse outcomes, while fewer individual barriers to
care and fewer than three complications on the MHC were
associated with lower odds for poor outcomes. Finally, in
the model for PROMIS Fatigue (tiredness), ever treated for
depression and higher pain severity were associated with
higher odds for worse reports of tiredness, while male gender and fewer access barriers to care were associated with
lower odds for tiredness.

Discussion
We hypothesized that patient and SCD-related factors as
well as barriers to care would independently contribute
to functioning as measured using PRO domains from the
ASCQ-Me®, PROMIS® and Neuro-QoL™ measurement
systems. We expected that the experience of pain and other
SCD-related complications would account for a significant
degree of the relation between the variables and the PRO
domains. Generally, our findings were consistent with study
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Table 3  Significant
multivariable relations between
patient-reported outcomes
and demographic and clinical
characteristics

Quality of Life Research (2022) 31:2681–2694
Model
ASCQ-Me® Emotional Impact

ASCQ-Me® Social Functioning Impact

ASCQ-Me® Pain Impact

ASCQ-Me® Sleep Impact

Neuro-QoL™ Cognitive Functioning

PROMIS® Emotional Distress

13

Predictor

OR (95% CI)

Ever treated for depression
# Individual barriers to care
0 versus 1 or more
ASCQ-Me® Pain Frequency
ASCQ-Me® Pain Severity
ASCQ-Me® SCD-MHC
Low (0–1)
Medium (2–3)
High (> 3)

2.30 (1.67–3.17)**

Employment
Disabled
Student
Other
Working
Ever treated for depression
# Individual barriers to care
0 versus 1 or more
ASCQ-Me® Pain Frequency
ASCQ-Me® Pain Severity
Employment
Disabled
Student
Other
Working
ASCQ-Me® Pain Frequency
ASCQ-Me® Pain Severity
Income
$25,000 and under
$25,001—$50,000
$50,001 +
Ever treated for depression
ASCQ-Me® Pain Frequency
ASCQ-Me® Pain Severity
ASCQ-Me® SCD-MHC
Low (0–1)
Medium (2–3)
High (> 3)
Income
$25,000 and under
$25,001—$50,000
$50,001 +
Ever treated for depression
# Accessl barriers to care
0- versus 1 or more
Income

0.50 (0.35–0.70)**
1.05 (1.03–1.07)**
1.07 (1.04–1.09)**
0.54 (0.33–0.86)**
0.49 (0.34–0.70)**
Ref.

3.65 (2.50–5.39)**
1.49 (0.87–2.51)
2.40 (1.62–3.58)**
Ref.
1.58 (1.18–2.13)*
0.54 (0.39–0.75)**
1.04 (1.03–1.06)**
1.08 (1.06–1.11)**

2.31 (1.68–3.2)**
1.05 (0.66–1.66)
2.05 (1.48–2.84)**
Ref.
1.10 (1.08–1.12)**
1.10 (1.08–1.12)**

1.92 (1.3–2.89)**
1.95 (1.24–3.1)**
Ref.
2.10 (1.56–2.81)**
1.03 (1.01–1.04)**
1.03 (1.01–1.05)**
0.43 (0.27–0.67)**
0.65 (0.48–0.89)*
Ref.

2.03 (1.36- 3.21)**
1.57 (0.97- 2.57)
Ref.
2.18 (1.61–2.93)**
0.57 (0.41–0.79)**
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Table 3  (continued)

Model

PROMIS® Fatigue/Tiredness
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Predictor

OR (95% CI)

$25,000 and under
$25,001—$50,000
$50,001 +
Ever treated for depression
# Individual barriers to care
0- versus 1 or more
ASCQ-Me® Pain Frequency
ASCQ-Me® SCD-MHC
Low (0–1)
Medium (2–3)
High (> 3)

1.97 (1.39–2.85)**
1.36 (0.88–2.09)
Ref.
3.28 (2.50–4.32)**

Gender Identity Male
Ever treated for depression
# Access barriers to care
0 versus 1 or more
ASCQ-Me® Pain Severity

0.38 (0.29–0.49)**
1.87 (1.47–2.39)**

0.46 (0.34–0.63)**
1.02 (1.01–1.04)**
0.62 (0.41–0.91)**
0.64 (0.47–0.86)**
Ref.

0.47 (0.36–0.62)**
1.02 (1.004–1.03)*

ASCQ-Me®: Adult Sickle Cell Quality of Life Measurement Information System
ASCQ-Me® SCD-MHC: ASCQ-Me®: Sickle Cell Disease Medical History Checklist
Neuro-QoL™: Quality of Life in Neurological Disorders
PROMIS®: Patient-Reported Outcomes Measurement Information System
*p < .01
**p < .001

a

All models were adjusted for gender, age group, and site. ORs for these variables were included in the
table only when statistically significant

hypotheses, with higher pain frequency and history of treatment for depression associated with higher odds of worse
outcomes in almost all PRO domains studied, with findings
remaining when controlling for age, gender and site. Such
socio-demographic variables as lower household income and
unemployment, particularly due to disability status, were
also associated with higher odds of worse outcomes on some
of the PRO domains. Our study includes consideration of
barriers to care, and we found that reports of fewer individual barriers to care were associated with better outcomes on
measures in the emotion domain. We also found that fewer
self-reported SCD complications/treatments were associated
with better outcomes in the emotion domain.
Our findings are consistent with previous research [5, 42,
43] that highlighted dimensions of pain experiences associated with worse outcomes on PROs for adults with SCD, as
well as depression [44, 45]. However, our study includes
the first large, multi-site cohort of adults with SCD who
completed contemporary PRO measures that have been
developed and validated with state-of-the-science psychometric methods. We thus contribute to the accumulation of
information on the precision, applicability and interpretation
of these next generation measurement systems.

Reports on the PRO measures for our study participants
were on average similar to reference samples, although with
considerable variability within and across domains. For
several domains, about 20% of participants of large-scale
PROMIS reference samples have demonstrated moderate
to severe symptomatology or functional impairment [46,
47]. About 20% of participants in the current study reported
moderate/severe pain, emotional impact or tiredness. However, the proportion of participants with moderate/severe
emotional distress (12.7%) and social functioning (14.8%)
and sleep impact (16.9%) on ASCQ-Me were less than that
seen in the reference population for PROMIS. In the current
study, the two measures therefore appear to be assessing different constructs, in contrast with a recent study including
42 adults who demonstrated severe impairments on most
domains assessed on both ASCQ-Me and PROMIS Global
Health measures [42]. The Esham sample also experienced
more severe and more frequent pain episodes compared with
the ASCQ-Me reference sample and the timing of administration of the PROs occurred in relation to hospital admissions, while the SCDIC Registry participants completed the
measures as outpatients.
Approximately 13% of respondents fell below the moderate/severe threshold on the Neuro-QOL Cognitive Function
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short form [35] which measures concerns about general cognition and executive function [48, 49]. The multivariable
model was consistent with prior studies in that worse reports
of cognitive function were associated with depressive symptoms and with lower incomes [50, 51]. Given that multiple
cognitive domains have been shown to be increasingly negatively affected across the lifespan for the SCD population,
this is an area of particular importance for future research
[52]. Further exploration is also needed of validity, reliability, interpretability, and responsiveness of scores from the
SCD specific ASCQ-Me measures and the comprehensive
measurement systems including PROMIS and Neuro-QOL
using large, multi-site samples [40].
Complex relations were also found among measures. Frequency of pain and history of depression were associated
with the highest odds for worse emotional and sleep impacts,
consistent with other studies [53, 54]. Pain experiences
combined with unemployment (particularly related to disabled status) played a significant role in worse outcomes on
social functioning. We consistently found that fewer patient
reports of SCD-related complications and treatments were
associated with better outcomes on the PRO measures. Thus,
when considering clinical and research interventions, there
is ample evidence that HRQoL in SCD must be viewed as a
complex biopsychosocial phenomenon and there is a need
for specific focus on pain experience and depression.
While disparities in HRQoL and quality of care are wellrecognized in SCD, particularly for adults [55, 56], the
impact of barriers to care has not been widely studied. We
used a modified version of the first disease-specific measure of barriers to care in SCD and demonstrated that most
participants in the SCDIC registry reported no barriers to
needed care, and fewer barriers to care were associated with
better outcomes on all PRO measures except pain and sleep
impact. In a recent study of 303 adults with SCD, and in
the SCDIC needs assessment with over 400 adolescents and
adults with SCD, the most reported barriers to receiving care
were costs, and perceived discrimination by and mistrust in
healthcare professionals [32, 57].

Limitations
Despite participation from multiple sites across the U.S.,
the generalizability of the sample may still represent a limitation, given that we used convenience sampling and the
majority were recruited through sickle cell centers and had
seen a sickle cell or primary care provider in the previous
year. Due to the shortage of adult sickle cell specialists in
the U.S., most adults with SCD do not have access to needed
preventive care. The impact of disparities in access to care
on HRQoL can only be determined when more patients who
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are “unaffiliated” with SCD care are recruited into research.
Barriers to health care access were reported in less than 20%
of our study population and this may be an underestimation
due to selection bias of patients who are already established
in specialized SCD centers.
The cross-sectional nature of the study precludes any
conclusions about causal relations between study variables
and the PROs. To reduce participant burden, we did not
include all items for every PRO measure, thereby limiting full comparison with studies using the complete PRO
measures. However, these measures have been constructed
to maintain precision even when single, or a few items are
used. Our registry data collection included both self-report
and information extracted from medical records, however
for completeness of data, we only used self-reports of SCD
complications experienced, and these reports may suffer
from recall bias or may not correspond with actual complications. Further, our reliance on self-report data poses the
potential risk of subjectivity and interindividual variation.
We did not have data on several potential contributing
factors to the PRO measures, such as other mental health
symptoms, e.g., anxiety; actual experience of stigma and
discrimination; chronic pain; coping and self-efficacy. We
acknowledge that our measure of depression is a self-report
of “ever received treatment for depression” so the prevalence of “depression” that we found on the order of 26%
may be an underestimate. We did not use data on healthcare
utilization from the medical record in these analyses given
excess missing data. Study limitations notwithstanding, our
research contributes to the literature in its examination of
inter-relations between modern PRO measures and SCDrelated and other variables within a conceptual model and
utilizing a large, geographically diverse sample.

Conclusions
Reliable and valid PRO measurement is essential to the design
of clinical trials and other research [58, 59]. Authoritative bodies including the Centers for Medicaid and Medicare Services
and the Food and Drug Administration have prioritized the use
of PRO measures for clinical and research applications [60,
61]. Results from this study can provide a baseline for longitudinal investigations that can establish sensitivity to change
of the PRO measures and advance our understanding of how
SCD and its treatments impact outcomes. We highlighted how
critical it is to view lives, care and treatments for individuals
with SCD within a biopsychosocial model given our sample’s
high prevalence of history of depression, impact of pain experiences in every PRO domain, yet positive associations with
fewer barriers to care and disease complications and interrelations between these variables and socio-demographics
such as income and employment status. This research supports
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that PRO measures can provide meaningful information for
providers and patients to improve HRQoL, as well as inform
multi-dimensional approaches for providing more effective
interventions to improve outcomes.
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